Online delivery of oral HIV pre- and post-exposure prophylaxis: findings from the ePrEP Kenya pilot

IF 4.9 1区 医学 Q2 IMMUNOLOGY
Catherine Kiptinness, Paulami Naik, Tabitha Kareithi, Nicholas Thuo, Phelix Okello, Carlos Culquichicon, Maeve Rafferty, Samira Abdulrashid, Edwin Jomo, Nicky Nyamasyo, Tony Wood, Rouella Mendonca, Rachel C. Malen, Julia C. Dettinger, Jillian Pintye, June Mwangi, Andy Stergachis, Jonah Onentia, Kelly Curran, Melissa Latigo Mugambi, Daniel Were, Kenneth Ngure, Monisha Sharma, Katrina F. Ortblad, the ePrEP Kenya team
{"title":"Online delivery of oral HIV pre- and post-exposure prophylaxis: findings from the ePrEP Kenya pilot","authors":"Catherine Kiptinness,&nbsp;Paulami Naik,&nbsp;Tabitha Kareithi,&nbsp;Nicholas Thuo,&nbsp;Phelix Okello,&nbsp;Carlos Culquichicon,&nbsp;Maeve Rafferty,&nbsp;Samira Abdulrashid,&nbsp;Edwin Jomo,&nbsp;Nicky Nyamasyo,&nbsp;Tony Wood,&nbsp;Rouella Mendonca,&nbsp;Rachel C. Malen,&nbsp;Julia C. Dettinger,&nbsp;Jillian Pintye,&nbsp;June Mwangi,&nbsp;Andy Stergachis,&nbsp;Jonah Onentia,&nbsp;Kelly Curran,&nbsp;Melissa Latigo Mugambi,&nbsp;Daniel Were,&nbsp;Kenneth Ngure,&nbsp;Monisha Sharma,&nbsp;Katrina F. Ortblad,&nbsp;the ePrEP Kenya team","doi":"10.1002/jia2.26468","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>The expansion of telecommunication networks and smartphones in many African countries could be leveraged to deliver HIV prevention products directly to consumers. In collaboration with a private e-commerce platform and online pharmacy in Kenya, MYDAWA, we piloted a new model of HIV pre- and post-exposure prophylaxis (PrEP/PEP) delivery.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>In the ePrEP Kenya pilot (NCT05377138), individuals living in Nairobi and Mombasa Counties could complete a free telehealth visit with a remote clinician to assess eligibility for online PrEP/PEP (i.e. ≥18 years; no medical contraindications). Eligible individuals could order HIV testing services—courier delivered to clients’ choice location—for a fee of 250 KES (∼$2 USD) for self-testing or 150 KES (∼$1 USD) for provider-administered rapid diagnostic testing. Following confirmation of clients’ HIV-negative status (via an uploaded test result image), free PrEP/PEP drugs from government supply were courier delivered with or separately from HIV testing services. Clients paid a delivery fee ≤149 KES (∼$1 USD) per courier visit.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>From October 2022 to December 2023, we screened 2257 individuals and enrolled 1915. Most PrEP/PEP clients were men (63%, 1428/1915), ≥25 years (72%, 1631/1915) and never married (80%, 1796/1915); few had ever used PrEP (3%, 48/1915) or PEP (14%, 263/1915). At enrolment, 227 (12%) were preliminarily eligible for PrEP and 1688 (88%) for PEP. Among PrEP-eligible clients, 89% (203/227) completed HIV testing and 92% (208/227) received PrEP; among PEP-eligible clients, 92% (1551/1688) completed HIV testing and 92% (1549/1688) received PEP. Most PrEP/PEP clients completed HIV testing within 6 hours of their telehealth visit (53%, 927/1757) and had drugs delivered with testing services (88%, 1546/1757). Among PrEP clients eligible for follow-up, 47% (120/256) continued PrEP and 4% (10/256) initiated PEP following PrEP discontinuation. Among PEP clients eligible for follow-up, 7% (99/1428) repeated PEP use and 6% (83/1428) transitioned from PEP to PrEP.).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Online PrEP/PEP delivery could expand access to prevention services by reaching individuals not engaged in existing delivery platforms. The uptake of online PEP was five times greater than PrEP, underscoring an unmet demand for PEP and highlighting the potential for online pharmacies to deliver time-sensitive PEP services.</p>\n </section>\n </div>","PeriodicalId":201,"journal":{"name":"Journal of the International AIDS Society","volume":"28 S1","pages":""},"PeriodicalIF":4.9000,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jia2.26468","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the International AIDS Society","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jia2.26468","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction

The expansion of telecommunication networks and smartphones in many African countries could be leveraged to deliver HIV prevention products directly to consumers. In collaboration with a private e-commerce platform and online pharmacy in Kenya, MYDAWA, we piloted a new model of HIV pre- and post-exposure prophylaxis (PrEP/PEP) delivery.

Methods

In the ePrEP Kenya pilot (NCT05377138), individuals living in Nairobi and Mombasa Counties could complete a free telehealth visit with a remote clinician to assess eligibility for online PrEP/PEP (i.e. ≥18 years; no medical contraindications). Eligible individuals could order HIV testing services—courier delivered to clients’ choice location—for a fee of 250 KES (∼$2 USD) for self-testing or 150 KES (∼$1 USD) for provider-administered rapid diagnostic testing. Following confirmation of clients’ HIV-negative status (via an uploaded test result image), free PrEP/PEP drugs from government supply were courier delivered with or separately from HIV testing services. Clients paid a delivery fee ≤149 KES (∼$1 USD) per courier visit.

Results

From October 2022 to December 2023, we screened 2257 individuals and enrolled 1915. Most PrEP/PEP clients were men (63%, 1428/1915), ≥25 years (72%, 1631/1915) and never married (80%, 1796/1915); few had ever used PrEP (3%, 48/1915) or PEP (14%, 263/1915). At enrolment, 227 (12%) were preliminarily eligible for PrEP and 1688 (88%) for PEP. Among PrEP-eligible clients, 89% (203/227) completed HIV testing and 92% (208/227) received PrEP; among PEP-eligible clients, 92% (1551/1688) completed HIV testing and 92% (1549/1688) received PEP. Most PrEP/PEP clients completed HIV testing within 6 hours of their telehealth visit (53%, 927/1757) and had drugs delivered with testing services (88%, 1546/1757). Among PrEP clients eligible for follow-up, 47% (120/256) continued PrEP and 4% (10/256) initiated PEP following PrEP discontinuation. Among PEP clients eligible for follow-up, 7% (99/1428) repeated PEP use and 6% (83/1428) transitioned from PEP to PrEP.).

Conclusions

Online PrEP/PEP delivery could expand access to prevention services by reaching individuals not engaged in existing delivery platforms. The uptake of online PEP was five times greater than PrEP, underscoring an unmet demand for PEP and highlighting the potential for online pharmacies to deliver time-sensitive PEP services.

Abstract Image

在线提供口服艾滋病毒暴露前和暴露后预防:ePrEP肯尼亚试点的结果
在许多非洲国家,电信网络和智能手机的扩大可以用来直接向消费者提供艾滋病毒预防产品。我们与肯尼亚的私人电子商务平台和在线药店MYDAWA合作,试行了一种新的艾滋病毒暴露前和暴露后预防(PrEP/PEP)递送模式。方法在ePrEP肯尼亚试点(NCT05377138)中,居住在内罗毕和蒙巴萨县的个人可以与远程临床医生完成免费远程健康访问,以评估在线PrEP/PEP的资格(即≥18岁;无医学禁忌症)。符合条件的个人可以订购艾滋病毒检测服务——快递送到客户选择的地点——自我检测费用为250肯尼亚先令(约2美元),提供者提供的快速诊断检测费用为150肯尼亚先令(约1美元)。在确认客户的艾滋病毒阴性状态后(通过上传的检测结果图像),政府供应的免费PrEP/PEP药物与艾滋病毒检测服务一起或单独快递。每次快递员上门,客户支付的快递费不超过149凯币(约1美元)。从2022年10月到2023年12月,我们筛选了2257人,入组1915人。大多数PrEP/PEP客户为男性(63%,1428/1915),年龄≥25岁(72%,1631/1915),未婚(80%,1796/1915);很少有人使用过PrEP(3%, 48/1915)或PEP(14%, 263/1915)。入组时,227人(12%)初步符合PrEP条件,1688人(88%)初步符合PEP条件。在符合PrEP条件的客户中,89%(203/227)完成了艾滋病毒检测,92%(208/227)接受了PrEP;在符合PEP条件的客户中,92%(1551/1688)完成了艾滋病毒检测,92%(1549/1688)接受了PEP。大多数PrEP/PEP客户在远程医疗访问后6小时内完成艾滋病毒检测(53%,927/1757),并在检测服务中获得药物(88%,1546/1757)。在符合随访条件的PrEP患者中,47%(120/256)继续PrEP, 4%(10/256)在PrEP停药后开始PEP。在符合随访条件的PEP患者中,7%(99/1428)重复使用PEP, 6%(83/1428)从PEP过渡到PrEP。结论在线PrEP/PEP服务可通过覆盖未使用现有服务平台的个人来扩大预防服务的可及性。在线PEP的使用率是PrEP的5倍,这突出了PEP的需求未得到满足,并突出了在线药店提供时效性PEP服务的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of the International AIDS Society
Journal of the International AIDS Society IMMUNOLOGY-INFECTIOUS DISEASES
CiteScore
8.60
自引率
10.00%
发文量
186
审稿时长
>12 weeks
期刊介绍: The Journal of the International AIDS Society (JIAS) is a peer-reviewed and Open Access journal for the generation and dissemination of evidence from a wide range of disciplines: basic and biomedical sciences; behavioural sciences; epidemiology; clinical sciences; health economics and health policy; operations research and implementation sciences; and social sciences and humanities. Submission of HIV research carried out in low- and middle-income countries is strongly encouraged.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信